Literature DB >> 16739355

Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer.

Nils Elander1, Peter Söderkvist, Karin Fransén.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are a group of matrix-degrading proteins implicated in several pathological processes, e.g., invasion and metastasis in malignant diseases such as colorectal cancer (CRC).
MATERIALS AND METHODS: One hundred and twenty-seven CRC patients and 208 controls were genotyped for MMP-1, -2, -3 and -9 promoter polymorphisms. The genotyping was performed with PCR/primer-extension/DHPLC or PCR/RFLP.
RESULTS: The MMP-1 2G allele was significantly associated with CRC (p=0.037). No significant association between CRC and MMP-2, -3 or -9 polymorphisms was evident. The analysis of polymorphisms in the clinicopathological subgroups displayed no significant associations.
CONCLUSION: The MMP-1 promoter polymorphism seems to affect the susceptibility to CRC, while MMP-2, -3 and -9 polymorphisms appear less likely to have any impact on CRC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16739355

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

1.  The polymorphism MMP1 -1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis.

Authors:  Lili Lu; Yujiao Sun; Yiqun Li; Ping Wan
Journal:  Tumour Biol       Date:  2014-11-13

2.  MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Xiao-Ou Shu; Jirong Long; Qiuyin Cai; Yongbin Xiang; Yu-Tang Gao; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2010-08-20       Impact factor: 4.872

3.  Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk.

Authors:  Yun Zhai; Wei Qiu; Xiao-Jia Dong; Xiu-Mei Zhang; Wei-Min Xie; Hong-Xing Zhang; Xiao-Yan Yuan; Gang-Qiao Zhou; Fu-Chu He
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

4.  Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan.

Authors:  Mei-Due Yang; Kuo-Cheng Lin; Meng-Chun Lu; Long-Bin Jeng; Chieh-Lun Hsiao; Te-Cheng Yueh; Chun-Kai Fu; Hsin-Ting Li; Shiou-Ting Yen; Chia-Wen Lin; Cin-Wun Wu; Su-Yi Pang; Da-Tian Bau; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2017-06-14

5.  Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics.

Authors:  Youwei Kou; Lei Qiao; Qiang Wang
Journal:  Tumour Biol       Date:  2014-11-21

6.  Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.

Authors:  Alexandra Mj Langers; Hein W Verspaget; Daniel W Hommes; Cornelis Fm Sier
Journal:  World J Gastrointest Oncol       Date:  2011-06-15

7.  Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Qiang Cao; Wei Wang; Chao Qin; Jun-Feng Wei; Yao-Jun Zhou; Yong-Fei Li; Min Tang; Wei-Min Liu; Wei Zhang; Jian-Gang Zou
Journal:  Mol Biol Rep       Date:  2011-06-30       Impact factor: 2.316

8.  The Contribution of Matrix Metalloproteinase-8 Promoter Polymorphism to Oral Cancer Susceptibility.

Authors:  Yi-Wen Hung; Chia-Wen Tsai; Cheng-Nan Wu; Liang-Chun Shih; Yen-Yu Chen; Yen-Fang Liu; Huey-Shan Hung; Ming-Yi Shen; Wen-Shin Chang; DA-Tian Bau
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

9.  Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma.

Authors:  Abdelbaset Buhmeida; Riyad Bendardaf; Marja Hilska; Yrjö Collan; Matti Laato; Stina Syrjänen; Kari Syrjänen; Seppo Pyrhönen
Journal:  J Gastrointest Cancer       Date:  2009

10.  The association of matrix metalloproteinase-1 genetic polymorphism (-1607 1G>2G) with colorectal cancer: a meta-analysis.

Authors:  Shu-Rong Ji; Jian-Jun Sun; Xin-Ping Li; Yi Zhang; Wen-Fang Liu
Journal:  Tumour Biol       Date:  2013-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.